30 minutes | Jan 14th 2021

Episode 143: #JPM21: Déjà vu in Alzheimer's research, and OWS's legacy

We're devoting this episode to the news coming out of the just-concluded J.P. Morgan Healthcare Conference, the drug industry's largest annual meeting. First, we'll dissect Eli Lilly's surprising data on a new Alzheimer's disease treatment and dig into its implications for the field. Then, we discuss whether there's a bubble inflating in the genome editing world, debate who will run the FDA under a President Biden, and consider the legacy of Moncef Slaoui, the outgoing leader of Operation Warp Speed.
Play
Like
Play Next
Mark
Played
Share